Sertindole was developed by the Danish pharmaceutical company H. Lundbeck and marketed under license by Abbott Labs.

Abbott Labs, the drug maker, gained 7/8, to 42 1/2, after besting analyst expectations by 1 cent a share.

He created the cholesterol-battling drug Niaspan, and sold to Abbott Labs in 2006 for $4.2 billion.

The results of a double blind study of an oral specific 5-lipoxygenase inhibitor, Zileuton (Abbott Labs) are disappointing.

Abbott Labs, together with the Calorie Control Council (a political lobby representing the diet foods industry), filed a second petition in 1982.

It is unclear whether this is at the request of Abbott Labs or because the petition is considered to be insufficient by the FDA.

This deal included Abbott Labs buying the vascular intervention business of Guidant for approximately $4.5 billion.

Abbott Labs "Ganaton"

And Abbott Labs rose 3 5/16 , to 50 7/8.

Abbott Labs responded by designing a system in which bottles with powdered drugs are screwed directly into the intravenous bag when needed.